Becton, Dickinson and Company $BDX Shares Sold by RBA Wealth Management LLC

RBA Wealth Management LLC reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 13.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 20,422 shares of the medical instruments supplier’s stock after selling 3,272 shares during the quarter. RBA Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $3,963,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BDX. Foster Victor Wealth Advisors LLC grew its position in shares of Becton, Dickinson and Company by 23.5% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 50,049 shares of the medical instruments supplier’s stock valued at $10,366,000 after buying an additional 9,526 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Becton, Dickinson and Company by 25.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,578 shares of the medical instruments supplier’s stock worth $1,471,000 after acquiring an additional 1,539 shares during the period. Sage Mountain Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $201,000. Tyche Wealth Partners LLC lifted its stake in shares of Becton, Dickinson and Company by 4.6% in the 4th quarter. Tyche Wealth Partners LLC now owns 1,812 shares of the medical instruments supplier’s stock worth $352,000 after acquiring an additional 79 shares during the period. Finally, Natural Investments LLC lifted its stake in shares of Becton, Dickinson and Company by 6.9% in the 4th quarter. Natural Investments LLC now owns 1,600 shares of the medical instruments supplier’s stock worth $310,000 after acquiring an additional 103 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BDX. Citigroup reduced their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a report on Friday, April 10th. They set a “neutral” rating and a $167.00 target price for the company. Piper Sandler restated a “neutral” rating and set a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Wells Fargo & Company dropped their target price on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a report on Tuesday, February 10th. Finally, Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $189.92.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $155.72 on Wednesday. The company has a market cap of $44.34 billion, a PE ratio of 25.40, a price-to-earnings-growth ratio of 11.06 and a beta of 0.29. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The company has a 50-day simple moving average of $169.00 and a 200-day simple moving average of $184.98.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were issued a dividend of $1.05 per share. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company declared that its board has approved a stock repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,713 shares of company stock worth $536,881 over the last three months. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.